NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above

NCT05406180

CompletedN/A

Sponsor: Sanofi

Conditions: Influenza

Interventions: VaxigripTetra inj.

Countries: South Korea

The objective is to describe the safety profile after 1 dose of VaxigripTetra inj. administered in subjects aged 3 years old and above under routine clinical practice. The planned duration of each subject's participation in the study will be 21 to 28 days.

Eligibility overview

Sex: ALL

Age: 3 Years to —

Healthy volunteers: Yes

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Aged 3 years and above on the day of enrollment
* For subjects aged 3 to 18 years: Informed consent form has been signed and dated by the parent or other legally acceptable representative.
* For subjects 19 years and above: Informed consent form has been signed and dated by the subject.
* Receipt of one dose of VaxigripTetra inj. (on the day of inclusion) as part of routine clinical practice according to the approved local product insert

Exclusion Criteria:

\- Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in a clinical study investigating a vaccine, drug, medical device, or medical procedure

Locations (10)

Donghae-si, Gangwon-do, South Korea
Changwon, South Korea
Gwangju, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Gyeonggi-do, South Korea
Incheon, South Korea
Incheon, South Korea
Incheon, South Korea
Seoul, South Korea